TGen Receives Approval for Patient Enrollment in Brain Cancer Clinical Trial

Glioblastoma (GBM) Pilot Trial funded by Ivy Foundation

In 2012, The Ben & Catherine Ivy Foundation awarded $10 million in grants for two groundbreaking brain cancer research projects at the Translational Genomics Research Institute (TGen). One of those projects has actually officially received the last regulatory approval from University of California, San Francisco, which means patient enrollment for the trial can easily begin.

In the $5-million-project, “Genomics Enabled Medicine in Glioblastoma Trial,” TGen and its clinical partners will certainly lead first-in-patient clinical trial studies that will certainly test promising brand-new drugs that may extend the survival of GBM patients. This multi-portion study will certainly take place in clinics across the country and TGen laboratories.

“GBM is one of the top three fastest-killing cancers out there and it affects individuals of all ages,” said Catherine (Bracken) Ivy, founder and president of The Ben & Catherine Ivy Foundation. “It is critical that we fund research that will certainly assistance patients live longer so we can easily study and treat brain cancer.”

The project begins along with a pilot study of 15 patients, using whole genome sequencing to study their tumor samples to assistance physicians find out just what drugs could be most beneficial.

To support molecularly informed clinical decisions, TGen labs additionally will certainly examine genomic data from at least 536 past cases of glioblastoma, as well as tumor samples from brand-new cases, producing tools that will certainly make a lot more recommendations in to exactly how glioblastoma tumors grow and survive. TGen additionally will certainly conduct a collection of pioneering lab examinations to measure cell-by-cell responses to various drugs.

“GBM is a disease that requires answers now, and we strongly believe those answers will certainly be found in the genome,” said Dr. David Craig, TGen’s Deputy Director of Bioinformatics, Director of TGen’s Neurogenomics Division, and one of the projects principal investigators. “Recognizing the genes that contribute to the survival of glioblastoma will certainly offer practical guide on exactly how to treat it, and might additionally lead to an improved understanding of just what drives others cancers as well.”

To get hold of brand-new treatments to patients as soon as possible, this five-year study will certainly include a feasibility study involving up to 30 patients, followed by Phase II clinical trials along with as numerous as 70 patients. TGen is teaming along with the Ivy Early Phase Clinical Trials Consortium that includes: University of California, San Francisco; University of California, Los Angeles; the MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; University of Utah; and the Dana-Farber/Harvard Cancer Center.

The results of these clinical trials ought to not only assistance the patients that join them, however additionally offer the data called for for FDA approval and availability of brand-new drugs that could benefit tens of thousands of brain cancer patients in the future.

“Working along with physicians, the project will certainly aim to understand treatment in the context of the tumor’s molecular profile. We will certainly have actually the opportunity to find out as quickly as combinations of drugs could be a lot more effective compared to using a single drug, rapidly identify which therapies don’t work, and accelerate discovery of ones that may prove promising for future development,” said Dr. John Carpten, TGen’s Deputy Director of Easy Science, Director of TGen’s Integrated Cancer Genomics Division, and an additional of the project’s principal investigators.

In addition to aiding patients as soon as possible, the project ought to significantly expand Arizona’s network of brain cancer experts.

# # #

About The Ben & Catherine Ivy Foundation
The Ben & Catherine Ivy Foundation, based in Scottsdale, Ariz., was formed in 2005, as quickly as Ben Ivy lost his battle along with glioblastoma multiforme (GBM). Due to the fact that then, the Foundation has actually contributed a lot more compared to $50 million to research in gliomas within the United States and Canada, along with the objective of much better diagnostics and treatments that offer long-term survival and a higher quality of life for patients along with brain tumors. The Ben & Catherine Ivy Foundation is the largest privately funded foundation of its kind in the United States. For a lot more information, visit http://www.ivyfoundation.org. We have actually regular updates via social media – please discover us on:
Blog: Ivy Foundation http://www.IvyFoundation.wordpress.com
Facebook: Ivy Foundation http://www.facebook.com/IvyFoundation
Twitter: @IvyFoundation https://twitter.com/IvyFoundation
Google+: Ivy Foundation https://plus.google.com/115330378249248717618/posts
LinkedIn: Ivy Foundation http://linkedin.com/company/the-ben-and-catherine-ivy-foundation
YouTube: IvyFoundationGBM http://www.youtube.com/user/IvyFoundationGBM

About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix-based non-profit organization dedicated to conducting groundbreaking research along with life changing results. Research at TGen is focused on aiding patients along with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working along with collaborators in the scientific and medical communities, TGen believes it can easily make a substantial supplement to the efficiency and effectiveness of the translational process. For a lot more information, visit: www.tgen.org.

Leave a Reply